InvestorsHub Logo
Followers 30
Posts 1475
Boards Moderated 0
Alias Born 07/10/2013

Re: Ubertino post# 74665

Friday, 10/04/2013 12:45:26 PM

Friday, October 04, 2013 12:45:26 PM

Post# of 146240
The extra step in NanoViricides, Inc. employed and patented mechanism makes it different from Clemsom's, right? What is your opinion?

Clemson researchers develop nanoparticle chicken feed is described as...

"...have built nanoparticles that mimic the host cell surface in poultry and locks to the targeted pathogens. The particles then bind together and are purged through the bowel. Tzeng calls it “intelligent chicken feed.” ~ Jeremy Tzeng and Clemson colleagues Fred Stutzenberger, Robert Latour Jr. and Ya-Ping Sun


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92663107

NanoViricides, Inc. describes nanoviricides employed mechanism as...

“We have developed a small chemical ligand that mimics both the mammalian (or a-2,6-) and avian (or a-2,3) forms of the native sialic acid receptor of influenza viruses. We can design a nanoviricide to exhibit several ligands at a single point, and each nanomicelle may exhibit several hundred ligands on its small surface. The ligands are designed to look very much like (mimic) the sialic acid to the influenza viruses, and the high density of the ligands would force the virus to land onto the nanoviricide and get destroyed by the hidden ‘tails’ of the nanomicelle that snap out and merge into the viral surface lipid coat.” ~ Dr. Anil Diwan, PhD, President and Chairman of NanoViricides, Inc.



“We have clearly demonstrated that the design platform technology for nanoviricides allows development of powerful broad-spectrum antiviral drugs,” said Anil R. Diwan, PhD, President and Chairman of NanoViricides, Inc."



The mechanism employed by NanoViricides, Inc. is different because of that extra step, namely, "...get destroyed by the hidden ‘tails’ of the nanomicelle that snap out and merge into the viral surface lipid coat.”

We have to take care of human kind first. Perhaps before FluCide gets approved to market by FDA expand the CGMP production capabilities, and at some point in the not-so-distant future they will branch out to produce Avian FluCide and other products to protect livestock from disease.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News